Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q5VYY2

UPID:
LIPM_HUMAN

ALTERNATIVE NAMES:
Lipase-like abhydrolase domain-containing protein 3

ALTERNATIVE UPACC:
Q5VYY2; A6PVS3; B2RXK7; B5MCR3

BACKGROUND:
The protein Lipase member M, alternatively named Lipase-like abhydrolase domain-containing protein 3, is essential for keratinocyte differentiation and lipid metabolism in epidermal layers. This specificity in function suggests a vital role in maintaining skin integrity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Lipase member M offers a promising pathway for developing new treatments. Given its essential role in the skin's lipid metabolism and cell differentiation, targeting this protein could lead to innovative therapies for skin conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.